MiMedx Group, Inc. (MDXG)
4.57
+0.14
(+3.16%)
USD |
NASDAQ |
Sep 04, 16:00
4.565
0.00 (0.00%)
Pre-Market: 20:00
MiMedx Group Research and Development Expense (Quarterly) : 2.777M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.777M |
| March 31, 2026 | 4.14M |
| December 31, 2025 | 4.761M |
| September 30, 2025 | 3.703M |
| June 30, 2025 | 3.303M |
| March 31, 2025 | 3.328M |
| December 31, 2024 | 3.571M |
| September 30, 2024 | 2.918M |
| June 30, 2024 | 3.012M |
| March 31, 2024 | 2.841M |
| December 31, 2023 | 2.434M |
| September 30, 2023 | 3.075M |
| June 30, 2023 | 3.672M |
| March 31, 2023 | 3.484M |
| December 31, 2022 | 5.40M |
| September 30, 2022 | 5.953M |
| June 30, 2022 | 5.512M |
| March 31, 2022 | 5.964M |
| December 31, 2021 | 4.575M |
| September 30, 2021 | 4.368M |
| June 30, 2021 | 4.063M |
| March 31, 2021 | 4.339M |
| December 31, 2020 | 3.434M |
| September 30, 2020 | 3.372M |
| June 30, 2020 | 2.259M |
| Date | Value |
|---|---|
| March 31, 2020 | 2.65M |
| December 31, 2019 | 2.719M |
| September 30, 2019 | 2.691M |
| June 30, 2019 | 2.828M |
| March 31, 2019 | 2.902M |
| December 31, 2018 | 4.54M |
| September 30, 2018 | 3.962M |
| June 30, 2018 | 3.719M |
| March 31, 2018 | 3.545M |
| December 31, 2017 | 3.47M |
| September 30, 2017 | 5.481M |
| June 30, 2017 | 4.747M |
| March 31, 2017 | 4.202M |
| December 31, 2016 | 3.456M |
| September 30, 2016 | 2.919M |
| June 30, 2016 | 3.168M |
| March 31, 2016 | 2.496M |
| December 31, 2015 | 2.341M |
| September 30, 2015 | 2.187M |
| June 30, 2015 | 2.054M |
| March 31, 2015 | 1.831M |
| December 31, 2014 | 1.846M |
| September 30, 2014 | 2.014M |
| June 30, 2014 | 1.800M |
| March 31, 2014 | 1.39M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 7.341M |
| Perspective Therapeutics, Inc. | 20.40M |
| ABVC BioPharma, Inc. | 0.0227M |
| Enovis Corp. | 31.69M |
| Edwards Lifesciences Corp. | 278.90M |